A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

被引：0

作者：

Atreya, Chloe E. ^{[1
]}

Ruiz-Saenz, Ana ^{[1
]}

Wang, Changjun ^{[1
]}

Pan, Bo ^{[1
]}

Dreyer, Courtney A. ^{[1
]}

Brunen, Diede ^{[2
]}

Prahallad, Anirudh ^{[2
]}

Spassov, Danislav ^{[1
]}

Steffen, Dana J. ^{[3
]}

Hann, Byron C. ^{[1
]}

VandenBerg, Scott R. ^{[1
]}

Gutkind, Silvio ^{[3
]}

Moasser, Mark M. ^{[1
]}

van't Veer, Laura J. ^{[1
]}

Coppe, Jean-Philippe ^{[1
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Netherlands Canc Inst, Amsterdam, Netherlands

[3] Univ Calif San Diego, San Diego, CA 92103 USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期

关键词：

D O I：

10.1158/1535-7163.TARG-19-B023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B023

引用

页数：3

共 35 条

[31] MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E
Tan, Xiang
Wu, Zuotao
Chen, Mingwu
ONCOTARGETS AND THERAPY, 2024, 17 : 307 - 312
[32] Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program.
Pellatt, Andrew Jared
Maddalena, Giulia
Eluri, Madhulika
Parseghian, Christine Megerdichian
Aziz, Kathryn
Alfaro, Kristin
Kell, Robert J.
Bent, Alisha Heather
Huey, Ryan W.
Uppal, Abhineet
Konishi, Tsuyoshi
Overman, Michael J.
Morelli, Maria Pia
Willis, Jason
Shen, John Paul Y. C.
Raghav, Kanwal Pratap Singh
Newhook, Timothy E.
Morris, Van K.
Dasari, Arvind
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 196 - 196
[33] Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naive metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study
Parikh, Aparna Raj
Chiorean, E. Gabriela
Atreya, Chloe Evelyn
Zheng, Lei
Kopetz, Scott
Spira, Alexander I.
Spigel, David R.
Cui, Yue
Osgood, Ryan
Tran, Rebecca
Morris, Shannon R.
Ulahannan, Susanna Varkey
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] Activation of receptor-interacting serine/threonine protein kinase-2 (RIP2K) via EGFR-mediated CRAF transactivation induces the acquired resistance to Dabrafenib in BRAF V600E mutant non-small cell lung cancer
Jang, Kangwon
Sohn, Jinyoung
Kim, Sung-Moo
Kim, Kyoung Jin
Cho, Byoung Chul
CANCER RESEARCH, 2015, 75
[35] Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers)
Lee, Michael Sangmin
Parikh, Aparna Raj
Spigel, David R.
Dayyani, Farshid
Spira, Alexander I.
Atreya, Chloe Evelyn
Ulahannan, Susanna Varkey
Strickler, John H.
Fakih, Marwan
Grierson, Patrick
Christenson, Eric
Outlaw, Darryl Alan
Khan, Gazala
Kopetz, Scott
Bullock, Andrea J.
Li, Zhengrong
Chen, Xiaoying
Patel, Hina
Hazra, Saswati
Chiorean, E. Gabriela
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 →